The use of GLP-1 RAs may be appropriate among select patients with psoriasis, although additional research is needed to guide ...

A cohort analysis finds that risankizumab shows the lowest risk for serious infections compared to other systemic therapies ...

Johnson & Johnson is counting on its newly launched psoriasis pill to become its next cash cow. Investors want to know if it ...

Psoriasis is a chronic skin disease that affects more than 8 million people in the U.S.Caused by an overactive immune system, ...

A review highlights new and emerging treatments for generalized pustular psoriasis, with a focus on IL-36 inhibitors.

Adding a dual GLP-1/GIP receptor agonist to the psoriasis drug ixekizumab (Taltz) significantly improved outcomes in adults ...

Investigators compared the risk for overall infection, serious infection, and infections of special interest in patients with psoriasis receiving biologics or oral small molecules.

Adults with moderate to severe psoriasis and overweight or obesity were more likely to achieve complete skin clearance plus ...

Adults with psoriasis who received text messages with guidance on diet, exercise and other lifestyle strategies engaged in ...

Among patients with psoriasis affecting special anatomical sites, IL-17 inhibitors are associated with significant improvements in PASI 75 and 90.

Tildrakizumab maintained efficacy and safety in obese patients with scalp psoriasis over 52 weeks. Find out more about the ...

Ixekizumab plus tirzepatide improved psoriasis clearance and weight loss in adults with obesity. Find out more about the ...